Business Context and Reporting Period
Company: Point Capital, Inc. (Note: Input metadata referenced "Silo Pharma," but the filing text identifies the registrant as Point Capital, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2015
Business Model: Closed-end, non-diversified Business Development Company (BDC) regulated under the Investment Company Act of 1940. The company invests in common stock, preferred stock, warrants, and convertible notes of small and mid-cap U.S. companies. It has elected to be treated as a Regulated Investment Company (RIC) for tax purposes.
Operations: The company has no full-time employees; executive officers provide services on a part-time basis. As of December 31, 2015, the portfolio consisted of 20 non-controlled, non-affiliated investments.
Key Financial Metrics
| Metric | 2015 | 2014 |
|---|---|---|
| Total Investment Income | $47,141 | $20,565 |
| Total Operating Expenses | $264,313 | $269,435 |
| Net Investment Loss | $(217,172) | $(248,870) |
| Net Realized Loss on Investments | $(200,468) | $92,277 (Gain) |
| Net Unrealized Appreciation | $8,142 | $(219,956) (Depreciation) |
| Net Decrease in Net Assets from Operations | $(409,498) | $(376,549) |
| Investments at Fair Value | $1,691,518 | $1,008,437 |
| Cash and Cash Equivalents | $722,764 | $1,739,520 |
| Total Assets | $2,450,236 | $2,771,532 |
| Total Liabilities | $90,756 | $2,554 |
| Net Assets | $1,959,480 | $2,368,978 |
| Net Asset Value (NAV) per Share | $0.04 | $0.05 |
Material Changes vs. Prior Period
- Portfolio Valuation: Investments at fair value increased by approximately 67.7% from 2014 to 2015, driven by new investments totaling $1.3 million, partially offset by sales and write-downs.
- Realized Losses: The company recorded a net realized loss of $200,468 in 2015, compared to a gain of $92,277 in 2014. A significant portion of the 2015 loss ($100,000) was due to the complete write-down of the investment in Arista Power, Inc., which was deemed to have zero fair value.
- Cash Position: Cash and cash equivalents decreased by $1.02 million (58.5%) from 2014 to 2015, primarily due to the purchase of new investments.
- Expense Structure: Total operating expenses remained relatively flat, though the composition shifted. Consulting fees of $174,000 in 2014 (related to stock issuance) were eliminated in 2015, replaced by $96,613 in compensation expenses (director fees and outsourced CFO services).
- NAV Decline: Net assets decreased by $409,498 in 2015, resulting in a NAV per share decline from $0.05 to $0.04.
Guidance, Risks, and Unusual Items
- Compliance Breach: The company disclosed it is currently in breach of its reporting obligations under the Exchange Act. It failed to file its Annual Report timely and was delinquent in filing the Quarterly Report for the quarter ended March 31, 2016. This breaches an agreement with the holder of Series A Convertible Preferred Stock, though no immediate default provisions (such as redemption) were triggered.
- Internal Control Weaknesses: Management identified material weaknesses in internal controls over financial reporting, including failure to timely recognize that shares issued to a consultant and options granted to directors in 2015 violated Section 23(a) of the Investment Company Act of 1940. These instruments were subsequently canceled.
- Liquidity and Capital: The company stated it has no agreements to raise capital and relies on existing cash to meet working capital requirements for at least 12 months. It may need to raise additional funds to continue investing, which could result in dilution.
- Portfolio Risks: Approximately 75% of the portfolio consists of securities not publicly traded, creating valuation uncertainty. The portfolio is concentrated in small-cap and private companies, exposing the company to significant liquidity and credit risks.
- Unusual Items: In 2015, the company reversed $62,758 of previously recorded compensation related to canceled director options and accrued $70,000 in cash fees for directors instead.
Investor Verification Checklist
- Reporting Status: Verify the current filing status of the company, specifically whether the delinquent Q1 2016 report has been filed and if the breach of the Preferred Stock agreement has been resolved.
- Internal Controls: Assess the remediation plan for the material weaknesses in internal controls, particularly regarding compliance with the Investment Company Act of 1940.
- Portfolio Valuation: Review the fair value methodology for the 75% of the portfolio held in non-public securities, given the significant write-down of Arista Power, Inc.
- Liquidity Runway: Confirm the company's ability to fund operations and new investments without raising additional capital, given the $722,764 cash balance and lack of committed financing.
- Preferred Stock Terms: Review the terms of the Series A Convertible Preferred Stock ($400,000 value) and the potential impact of the reporting breach on conversion rights or redemption triggers.